Rapamycin

—

evidence score

other

Prescription Only

sirolimusRapamuneeverolimus (analog)+1 more

Rapamycin (sirolimus) is an FDA-approved immunosuppressant that is also the most evidence-backed longevity drug in existence. It is the only drug proven to extend lifespan in already-aged mammals — starting at 20 months (equivalent to ~60 human years), mice receiving rapamycin showed 9-14% increased maximum lifespan. The mechanism is mTORC1 inhibition, which mimics dietary restriction. Weekly or biweekly low-dose protocols are being studied and used off-label by longevity physicians (Dr. Peter Attia, PEARL trial) to avoid the immunosuppressive dose side effects. The PEARL trial is the first placebo- controlled longevity trial in healthy humans. Age-related conditions showing benefit include declining vaccine immune response reversal, cardiac aging, and physical function.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

5 mg

1 mgRange10 mg

Frequencyonce weekly or every 2 weeks (off-label longevity protocol)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~62 hours

OnsetmTOR inhibition within hours; longevity-related effects chronic (months-years)

DurationOnce-weekly dosing maintains intermittent mTOR inhibition

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Rapamycin is currently categorized as a other compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

FKBP12 binding → mTORC1 inhibition → reduced protein synthesis, increased autophagy, reduced senescence-associated secretory phenotype (SASP), improved lysosomal function

Practical Context

Strongest current signals

No indexed study summaries yet.

Elevated caution signals

1 severe/high side effect flag